The gliptins- a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by inhibiting the enzyme dipeptidyl peptidase 4, which increases the circulating levels of incretins that can boost insulin levels. In this exclusive KOL Interview , Dr. Raghu Satyanarayan talks on ‘Insulin, Gliptins And Diabetes Management’ Dr.
Raghu Satyanarayan is an eminent Consulting Physician from Ahmedabad in Gujarat and is associated with Sterling Hospital. He is also a member of IMA, APA and RSSDI.
